Azitra prioritizes pipeline and reports $3.3 million net loss for the second quarter 2026

Azitra reported a net loss of $3.3 million for the second quarter of 2026 as the company strategically prioritized its clinical pipeline toward programs with near-term catalysts. The firm is shifting focus toward its ATR-COSF cosmetic program and ATR-04 therapeutic candidate while pausing its Netherton syndrome study to preserve capital.

Key Highlights

• Cash and cash equivalents totaled $6.7 million as of June 30, 2026, providing a runway for upcoming clinical milestones.
• General and administrative expenses increased to $2.1 million compared to $1.5 million in the prior year, primarily driven by professional fees.
• Topline data from the first cohort of the Phase 1/2 clinical trial evaluating ATR-04 for EGFR inhibitor-associated rash is expected in the fourth quarter of 2026.